Evidence map›Paper›PMID 27646470›Full record

ReviewBritish journal of pharmacology2016

Understanding how long-acting β

Robert Newton, Mark A Giembycz

Open access · bronzeAbstract readReview
In one paragraph

Review in British journal of pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Pharmacometabolomics of Asthma as a Road Map to Precision Medicine.Handbook of experimental pharmacology · 2023
    Article
  6. Recent Advances in Nanomaterials for Asthma Treatment.International journal of molecular sciences · 2022
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Potentiation of long-acting βRespiratory research · 2021
    Article
  13. Activation of βArchives of pharmacal research · 2021
    Review
  14. Can GPCRs Be Targeted to Control Inflammation in Asthma?Advances in experimental medicine and biology · 2021
    Article
  15. Article
  16. Glucocorticoids rapidly activate cAMP production via GFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020
    Article
  17. Article
  18. Long-ActingMolecular pharmacology · 2018
    Article
  19. Article
  20. A bronchoprotective role forAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Robert NewtonDepartment of Cell Biology and Anatomy, Airways Inflammation Research Group, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.ORCID 0000-0002-4919-8498
Mark A GiembyczDepartment of Physiology and Pharmacology, Airways Inflammation Research Group, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
University of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In moderate-to-severe asthma, adding an inhaled long-acting β

Indexed as

Administration, InhalationAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsAnti-Inflammatory AgentsAsthmaHumansInflammationAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsAnti-Inflammatory Agents

Identifiers

PMID27646470
PMCPMC5120156
OpenAlexW2523576980

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.